INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death globally. Researchers estimate that roughly 1.4 million new cases of CRC will be diagnosed and 694000 deaths will result from CRC per year [1] . Despite improvements in multimodal anticancer strategies, the prognosis of advanced CRC is still poor, with 5-year survival rates for stage III and stage IV colon cancer at 65.4% and 12.8%, respectively [2] . A detailed understanding of the biological processes that modulate the progression and metastasis of CRC may provide new molecular pathogenesis targets for CRC diagnosis and benefit anti-tumor therapy.
The calcium ion (Ca 2+ ) is a ubiquitous intracellular signal responsible for a broad range of cellular events, such as cell growth, cytoskeletal organization, regulation of synaptic transmission, and Ca 2+ homeostasis [3] . The Ca 2+ /calmodulin (CaM)-dependent protein kinases (CaMKⅠ, CaMKⅡ and CaMKⅣ) are multifunctional serine/threonine kinases whose activity is activated upon Ca 2+ /CaM binding [4] . The upstream CaMK kinases (CaMKKs) phosphorylate a critical Thr 200 in the activation-loop to activate CaMKIV, whereas CaMKII is fully activated by the autophosphorylation of its own Thr 286 [5] . Studies have revealed that the calcium signal is involved in cancer cell proliferation, invasion, tumor growth and metastasis [6] [7] [8] [9] . However, fewer studies have focused on CaMKII, one of the most important sensors and regulators of the Ca 2+ signal, in digestive cancers, especially in CRC.
In the present study, we first demonstrated that CaMKII was over-expressed in human colon cancers and was associated with cancer differentiation. We further sought to investigate the role of CaMKII in human colon cancer proliferation and migration. The results revealed that in the human colon cancer cell line HCT116, the CaMKII-specific inhibitor KN93, but not its inactive analogue KN92, decreased cancer cell proliferation. KN93 also significantly prohibits HCT116 cell migration and invasion. Additionally, we determined that CaMKII inhibition decreased the phosphorylation of ERK1/2 and p38. The specific inhibition of ERK1/2 or p38 decreased the proliferation and migration of colon cancer cells. These findings highlight CaMKII as a potential critical mediator in human colon tumor development and metastasis.
MATERIALS AND METHODS

Reagents
Antibodies against CaMKIIα, ERK1/2, phospho (p)-ERK1/2, p38, p-p38, MMP2, MMP9, TIMP-1 and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States). KN-93 (2- 
and SB203580 were obtained from Calbiochem (La Jolla, CA, United States). Other chemicals of the highest purity were purchased from Sigma (St. Louis, MO, United States).
Tissue samples
Colon tissue samples were obtained from the Department of Gastrointestinal Surgery at Renmin Hospital of Wuhan University in accordance with local ethics committees. All samples were obtained from the primary colon sites of pretreatment cases of paracancerous lesions (n = 5), well-differentiated colon cancer tissues (n = 6) and poorly differentiated colon cancer tissues (n = 6). All samples were analyzed and assessed by two histological specialists working blindly. for 45 min at room temperature with secondary antibodies. Visualization was achieved with the DAB (3,3'-diaminobenzidine) detection kit, and the cell nuclei were counterstained using hematoxylin. After staining, five fields (at a magnification of × 100) were randomly selected in each slide. Staining was quantified with Image J software and evaluated by two investigators following the "blinded" principle.
Cell culture and treatment
MTT assay
Cell 
Western blot analysis
Protein from unstained paraffin-embedded samples was deparaffinized and rehydrated via successive washes in xylene/ethanol and water. After incubation in extraction buffer at 100 ℃ for 20 min followed by a 2 h incubation at 80 ℃, proteins were obtained by centrifugation. Whole cell lysates were prepared with RIPA lysis buffer containing protease and phosphatase inhibitor cocktail. Protein concentrations of cell lysates were determined with the bicinchoninic acid protein assay. A total of 30-40 μg of lysate were loaded onto a 10% SDS-PAGE gel and subjected to gel electrophoresis. Resolved proteins were transferred to a polyvinylidine fluoride membrane. Membranes were then blocked in 5% non-fat dry milk in Trisbuffered saline with Tween (TBS-T) for 1 h and then incubated with antibodies to GAPDH, CaMKIIα (Cell Signaling Technology), ERK1/2, phospho-ERK1/2, p38, p-p38, MMP2, MMP9 and TIMP-1 at 4 ℃ overnight.
Membranes were washed with TBS-T and then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blotting bands were visualized with enhanced chemiluminescence. GAPDH was used as a loading control.
Quantitative real-time PCR
Cells were seeded at 10 6 cells per 10 cm dish and were allowed to grow to 80% confluency in complete media. Cells were removed with 0.025% ethylenediaminetetraacetic acid and centrifuged for 5 min at 1100 rpm. Cell pellets were resuspended in 1 mL of 
Migration and invasion assay
RESULTS
CaMKII is over-expressed in colon cancers
The expression of CaMKⅡ was evaluated by IHC with a monoclonal CaMKⅡ antibody on sections obtained from formalin-fixed, paraffin-embedded samples of paracancerous tissue, well-differentiated colon cancer samples and poorly differentiated colon cancer samples. As expected, CaMKⅡ was significantly overexpressed in the poorly differentiated colon cancer samples and well-differentiated cancer samples compared to the paracancerous tissues ( Figure 1A) . A quantification assay suggested that the expression of CaMKⅡ was highest in poorly differentiated colon cancer tissues. We further evaluated CaMKII protein and mRNA levels in cancer and paracancerous assays, cells were cultured in DMEM containing 10% FBS with the indicated treatment. After incubation at 37 °C for 24 h, migrated cells were fixed and stained with the Diff-Quik stain and counted in four random fields. The experiments were performed in triplicate wells, and each experiment was performed at least two or three times as indicated.
Wound-healing assay
A wound-healing assay was performed with 6-well plates. HCT116 cells were seeded at confluency 24 h before the experiment. The cell layers were carefully scratched with 200-mL sterile pipette tips and washed twice with fresh medium. The cells were photographed under a light microscope at × 200 magnification 24 h later.
Statistical analysis
All experiments were performed in triplicate. Data are expressed as the mean ± SD. Differences between Figure 1B and C) . We deduced that CaMKII may be a potential regulator in colon cancer development.
CaMKII is required for colon cancer proliferation and migration
CaMKII has been shown to drive cancer growth and metastasis. To ascertain whether CaMKII regulates Western blot analysis of ERK1/2, phosphor-ERK1/2, p38 and phosphor-p38; C: Immigration and invasion analysis by T transwell assay. All data are presented as the mean ± standard error SE of at least three independent experiments. a P < 0.05, vs control group. 
C
colon cancer proliferation and migration, the CaMKII specific inhibitor KN93 was selected. Human colon cancer HCT116 cells were treated with KN93, and its inactive analogue, KN92, was used as an additional control. We found that KN93 inhibited colon cancer cell proliferation (Figure 2A) . Importantly, in migration and invasion experiments, the motility of HCT116 cells was significantly attenuated (Figure 2B and C) . Furthermore, CaMKII inhibition decreased MMP2 and MMP9 expression at both transcriptional and posttranscriptional levels. The opposite results were detected for TIMP-1 expression ( Figure 2D and E) . Thus, we concluded that CaMKII is required for colon cancer cell proliferation and migration.
CaMKII regulates colon cancer cell proliferation and migration via ERK1/2 and p38-dependent pathways
We further investigated the molecular mechanism of CaMKII regulation in human colon cancer cells. As shown in Figure 3 , KN93, but not KN92, decreased the phosphorylation of ERK1/2 and p38, which are involved in colon cancer development. Pretreatment with specific inhibitors of ERK1/2 or p38 (PD98059, SB203580) decreased HCT116 cell proliferation, migration and invasion. These data demonstrated that the effects of CaMKII on human colon cancer are ERK1/2-and p38-dependent. Taken together, these results indicate that CaMKII is an important regulator of human colon cancer growth and migration.
DISCUSSION
It is widely accepted that intracellular Ca 2+ signaling pathways regulate various biological events, including cell proliferation, motility, activation and differentiation, during cancer development [10, 11] . In the present study, we demonstrated that CaMKII is over-expressed in colon cancers and highly expressed in poorly differentiated colon tumors. We highlight the role of CaMKII in colon cancer growth and metastasis.
CaMKII inhibitors can inhibit CaMKII activity by interacting with the Ca 2+ /CaM-binding site or interfering with its catalytic activities. Previous studies revealed that CaMKII-specific inhibitors such as KN-62, KN-93, and autocamtide 2-related inhibitory peptide inhibit CaMKII-dependent processes in tumor and normal cells, causing cell cycle arrest, cellular apoptosis, or the inhibition of cell proliferation [12] [13] [14] . Some studies have implicated CaMKII as an important player in cancer cell proliferation. CaMKII inhibition decreased ovarian cancer cell motility and decreased tumor growth and metastasis [15] . The in vivo administration of KN-93 to mice xenografted with human osteosarcoma cells significantly decreased intratibial and subcutaneous tumor growth [16] . In CRC, we demonstrated that CaMKII inhibition strongly inhibited human colon cancer cell proliferation ( Figure  2A) .
Recent studies support the important role of CaMKII in cancer invasion and metastasis. The up-regulation of CaMKIIα was found in primary osteosarcoma tissues from patients and in aggressive osteosarcoma cell lines [17] . CaMKIIα depletion decreased motility and invasion, whereas CaMKIIα over-expression increased the tumorigenic properties of osteosarcoma cells in vitro. Our current results revealed the important role of CaMKII in colon cancer migration and invasion. KN93 dramatically decreased the expression of MMP2 and MMP9, increased TIMP-1 levels and prohibited the invasive motility of colon cancer cells ( Figure  2 ). CaMKII is a critical regulator of colon cancer progression.
The MAPK pathway is one of the important downstream targets in CaMKII regulation [4] . CaMKII directly or indirectly up-regulated multiple signaling pathways, such as ERK1/2, AKT1 and β-catenin, and is involved in regulating the survival and proliferation of nonsmall cell lung cancer cells [6] . We further investigated whether ERK1/2 and p38 were involved in CaMKII pathways. Our data showed that the inhibition of CaMKII by KN93 significantly decreased ERK1/2 and p38 phosphorylation (Figure 3) . The specific inhibition of ERK1/2 or p38 decreased the proliferation, migration and invasion of HCT116 cells. Therefore, CaMKII mediates colon cancer growth and migration via ERK1/2-and p38-dependent pathways.
Taken together, the current study provided evidence for CaMKII as a pivotal regulator of colon cancer cell proliferation and migration. CaMKII is a potentially important target in CRC treatment.
COMMENTS
Background
Ca
2+ /calmodulin (CaM)-dependent protein kinase II (CaMKII) is one of the most important sensors and regulators of the Ca 2+ signal which is involved in cancer cell proliferation, invasion, tumor growth and metastasis. Despite the critical role of CaMKII, fewer studies focus on it in digestive cancers, especially in colorectal cancer.
Research frontiers
Recently, studies have revealed CaMKII is an effective controller in ovarian cancer and osteosarcoma cell motility, cell growth and metastasis.
Innovations and breakthroughs
In the present study, the authors demonstrated that CaMKII was over-expressed in human colon cancers and was associated with cancer differentiation. Meanwhile, in the human colon cancer cell line HCT116, the CaMKII-specific inhibitor KN93, but not its inactive analogue KN92, decreased cancer cell proliferation. CaMKII inhibition also significantly prohibited colon cancer cell migration and invasion. Additionally, ERK1/2 and p38 were the targets of CaMKII regulation.
Applications
These findings highlight CaMKII as a potential critical mediator in human colon tumor development and metastasis. Its relationship to colon cancer
